# A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Source: https://onco.cc/trials/nct06055439/  
OnCo record `nct06055439` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CHM-2101 CAR-T cells in neuroendocrine tumours, colorectal cancer and gastric & gastro-oesophageal junction cancer, run by Chimeric Therapeutics, now recruiting.

## Summary

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy is a phase 1/2 interventional study registered as NCT06055439 by Chimeric Therapeutics, with 135 participants planned, started 2024-05-15 and due to reach its primary completion in 2026-05. Interventions recorded: CHM-2101 CAR-T cells.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06055439
- Phase: 1/2
- Setting: A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of Relapsed or Refractory Gastrointestinal Cancers
- Sponsor: Chimeric Therapeutics
- Enrolled: 135

## Sources

- ClinicalTrials.gov NCT06055439: https://clinicaltrials.gov/study/NCT06055439

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)

---
JSON: https://onco.cc/api/v1/entities/nct06055439.json